{"slideshow_credits": null, "snippet": "Elan, the embattled Irish drug company, said on Monday that an unsolicited takeover bid by Royalty Pharma had lapsed because Elan\u2019s shareholders had voted in favor of a share buyback plan.", "abstract": "Elan, the embattled Irish drug company, said on Monday that an unsolicited takeover bid by Royalty Pharma had lapsed because Elan\u2019s shareholders had voted in favor of a share buyback plan.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Julia", "role": "reported", "lastname": "WERDIGIER", "rank": 1, "organization": ""}], "original": "By JULIA WERDIGIER"}, "web_url": "http://dealbook.nytimes.com/2013/06/17/battle-for-elan-in-doubt-after-shareholders-approve-buyback-plan/", "lead_paragraph": null, "headline": {"main": "Battle for Elan in Doubt After Share Buyback Plan Is Approved", "kicker": "DealBook"}, "_id": "51bf00b57e0d9c0839d28ebc", "word_count": "299", "multimedia": [], "pub_date": "2013-06-17T08:22:16Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Elan Corporation PLC", "rank": "1"}, {"name": "organizations", "value": "Royalty Pharma", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}